TY - JOUR
T1 - Prognostic Role of a New Index Tested in European and Korean Advanced Biliary Tract Cancer Patients: the PECS Index.
AU - Rovesti, Giulia
AU - Leone, Francesco
AU - Brandi, Giovanni
AU - Fornaro, Lorenzo
AU - Scartozzi, Mario
AU - Niger, Monica
AU - Yoo, Changhoon
AU - Caputo, Francesco
AU - Filippi, Roberto
AU - Casagrande, Mariaelena
AU - Silvestris, Nicola
AU - Santini, Daniele
AU - Faloppi, Luca
AU - Palloni, Andrea
AU - Aglietta, Massimo
AU - Vivaldi, Caterina
AU - Cho, Hyungwoo
AU - Lai, Eleonora
AU - Fenocchio, Elisabetta
AU - Nichetti, Federico
AU - Pella, Nicoletta
AU - De Lorenzo, Stefania
AU - Di Maio, Massimo
AU - Vasile, Enrico
AU - de Braud, Filippo
AU - Jeong, Jae Ho
AU - Aprile, Giuseppe
AU - Orsi, Giulia
AU - Cascinu, Stefano
AU - Casadei-Gardini, Andrea
N1 - Publisher Copyright:
© 2021, Springer Science+Business Media, LLC, part of Springer Nature.
Copyright:
Copyright 2021 Elsevier B.V., All rights reserved.
PY - 2022
Y1 - 2022
N2 - Background and Aim: The aim of the present study is to evaluate a new index (PECS (PsECogSii)index) influenced by PS ECOG and systemic immune-inflammation index (SII) in unresectable locally advanced or metastatic BTC patients treated with first-line chemotherapy. Methods: This multicenter, international, study was conducted on a training cohort of 130 patients and in three European and Korean validation cohorts The PECS index was calculated as ECOG × SII index (neutrophil count × platelet count/lymphocyte count). Event-time distributions were estimated using the Kaplan–Meier method and survival curves were compared using the log-rank test. Results: In the training cohort, the median overall survival (mOS) was 13.2 months, 8.7 months, and 3.8 months for patients with PECS-0, PECS-1, and PECS-2, respectively (PECS-0: HR = 1; PECS-1: HR 1.41; PECS-2: HR 3.23) (p < 0.0001). In the first validation cohort, the mOS was 12.8 months, 10.1 months, and 5.3 months for patients with PECS-0, PECS-1, and PECS-2, respectively (PECS-0: HR = 1; PECS-1: HR 1.29; PECS-2: HR 2.40) (p < 0.0001). In the second validation cohort, the mOS was 21.2 months, 10.2 months, and 3.0 months for patients with PECS-0, PECS-1, and PECS-2, respectively (PECS-0: HR = 1; PECS-1: HR 2.25; PECS-2: HR 9.00) (p < 0.0001). In the third validation cohort, the median OS was 15.5 months, 7.5 months, and 3.7 months for patients with PECS-0, PECS-1, and PECS-2, respectively (PECS-0: ref HR = 1; PECS-1: HR 2.14; PECS-2: HR 5.00) (p < 0.0001). Multivariate analysis in all cohorts confirmed the PECS index as an independent prognostic factor for OS. Conclusions: The easy assessment, low cost, and reproducibility make PECS index a promising tool to assess the prognosis of BTC patients in future clinical practice.
AB - Background and Aim: The aim of the present study is to evaluate a new index (PECS (PsECogSii)index) influenced by PS ECOG and systemic immune-inflammation index (SII) in unresectable locally advanced or metastatic BTC patients treated with first-line chemotherapy. Methods: This multicenter, international, study was conducted on a training cohort of 130 patients and in three European and Korean validation cohorts The PECS index was calculated as ECOG × SII index (neutrophil count × platelet count/lymphocyte count). Event-time distributions were estimated using the Kaplan–Meier method and survival curves were compared using the log-rank test. Results: In the training cohort, the median overall survival (mOS) was 13.2 months, 8.7 months, and 3.8 months for patients with PECS-0, PECS-1, and PECS-2, respectively (PECS-0: HR = 1; PECS-1: HR 1.41; PECS-2: HR 3.23) (p < 0.0001). In the first validation cohort, the mOS was 12.8 months, 10.1 months, and 5.3 months for patients with PECS-0, PECS-1, and PECS-2, respectively (PECS-0: HR = 1; PECS-1: HR 1.29; PECS-2: HR 2.40) (p < 0.0001). In the second validation cohort, the mOS was 21.2 months, 10.2 months, and 3.0 months for patients with PECS-0, PECS-1, and PECS-2, respectively (PECS-0: HR = 1; PECS-1: HR 2.25; PECS-2: HR 9.00) (p < 0.0001). In the third validation cohort, the median OS was 15.5 months, 7.5 months, and 3.7 months for patients with PECS-0, PECS-1, and PECS-2, respectively (PECS-0: ref HR = 1; PECS-1: HR 2.14; PECS-2: HR 5.00) (p < 0.0001). Multivariate analysis in all cohorts confirmed the PECS index as an independent prognostic factor for OS. Conclusions: The easy assessment, low cost, and reproducibility make PECS index a promising tool to assess the prognosis of BTC patients in future clinical practice.
KW - Biliary tract cancer
KW - Chemotherapy
KW - Cholangiocarcinoma
KW - Gallbladder cancer
KW - Prognosis
KW - Prognostic index
KW - Survival
UR - http://www.scopus.com/inward/record.url?scp=85100560888&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85100560888&partnerID=8YFLogxK
U2 - 10.1007/s12029-021-00596-z
DO - 10.1007/s12029-021-00596-z
M3 - Article
AN - SCOPUS:85100560888
JO - Journal of Gastrointestinal Cancer
JF - Journal of Gastrointestinal Cancer
SN - 1941-6628
ER -